Search results
Inhaled Insulin Could Help Folks With Type 1 Diabetes Avoid Needles
Fox Bangor· 15 hours agoInhaled insulin could be a better option than injections or pumps for some patients with type 1...
The 10 Best Performing Stocks So Far In 2024
Forbes· 3 days agoThe stocks have been on a tear with year-to-date gains ranging from 387% to more than a jaw-dropping 1,100% (as of June 14’s market close). The stock market has been buoyant in 2024, debunking ...
‘My husband had a stent fitted on holiday – but Co-op won’t pay his £10k hospital bill’
The Telegraph via Yahoo News· 3 days agoSince our return, my husband has been treated by the NHS for obstructive jaundice complicated by ...
RenovoRx (NASDAQ:RNXT) Receives New Coverage from Analysts at Ascendiant Capital Markets
ETF DAILY NEWS· 7 days agoAscendiant Capital Markets assumed coverage on shares of RenovoRx (NASDAQ:RNXT – Free Report) in a report issued on Monday morning, Benzinga reports. The firm issued a buy rating and a $8.00 ...
Zentalis Pharmaceuticals’ (ZNTL) “Equal Weight” Rating Reaffirmed at Morgan Stanley
ETF DAILY NEWS· 6 days agoMorgan Stanley restated their equal weight rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note published on Tuesday morning, MarketBeat reports. Other ...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 5 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wedbush
ETF DAILY NEWS· 6 days agoWedbush downgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from a neutral rating to an underperform rating in a research report sent to investors on Tuesday morning, MarketBeat ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by UBS Group
ETF DAILY NEWS· 5 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday, Briefing.com reports. UBS Group ...
Oppenheimer Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $25.00
ETF DAILY NEWS· 6 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective trimmed by Oppenheimer from $50.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports. Wells Fargo ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $20.00 at HC Wainwright
ETF DAILY NEWS· 6 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective cut by HC Wainwright from $40.00 to $20.00 in a report issued on Tuesday morning, Benzinga reports. Stifel Nicolaus ...